Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, announces it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC ( “Concentra”) will acquire Allakos for $0.33 in cash per share of Allakos common stock (“Allakos Common Stock”). Allakos’ Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos’ Transaction Committee, has approved the Merger Agreement and related transactions.
Read the full article: Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share //
Source: https://www.globenewswire.com/news-release/2025/04/02/3054176/0/en/Allakos-Inc-Enters-into-Agreement-to-Be-Acquired-by-Concentra-Biosciences-LLC-for-0-33-in-Cash-per-Share.html